Mayor Turner recognized nationally for progress of moving Houston toward resiliency

Turner's plans

Mayor Sylvester Turner was just named chairman of the Resilient Cities Network. Photo courtesy of The Ion

In the past five years, six federally declared flooding disasters have wreaked havoc in Houston — most notably Hurricane Harvey in 2017. Now, you might say Houston stands tall as a hub of resilience when it comes to disaster preparedness and myriad other pressing issues.

The Texas chapter of the American Planning Association recently honored Mayor Sylvester Turner's Resilient Houston initiative as the top entry in the resilience category of the chapter's annual awards program. In addition, Turner was just named chairman of the Resilient Cities Network.

With backing from Shell Oil Co., the City of Houston hired its first chief resilience officer, Marissa Aho, in 2019 and developed a multibillion-dollar resilience strategy to address threats from hurricanes, tropical storms, floods, and climate change. The plan also seeks to boost the resilience of Houston's economy, neighborhoods and natural resources.

"Our efforts need to be bold, transformative, and aligned to achieve the outcomes Houstonians deserve," Turner said in unveiling the resilience plan in February. "Resilient Houston is a framework for transformative change that comes from thinking and acting together to build and grow Houston's long-term resilience. We will need our partners and every Houstonian at the table to achieve this vision."

Dallas and El Paso also have resilience plans in place.

Houston's resilience effort outlines a number of ambitious goals, such as:

  • Updating city building codes and standards by 2030 to reduce damage from disasters.
  • Attracting or incubating 50 Energy 2.0 companies in the Houston area by 2025.
  • Planting 4.6 million new native trees by 2030.
  • Building at least 375,000 homes in Houston for all income levels by 2050.
  • Providing all Houstonians with easy access to high-frequency public transportation by 2050.

As explained by Rice University's Kinder Institute for Urban Research, hurricanes and floods are examples of "acute shocks" in terms of resilience. These are sudden, large-scale events that disrupt and endanger life. Other shocks include economic crisis, cyberattacks, terrorism, chemical disasters, and extreme heat.

The Kinder Institute points out that Houston's resilience strategy not only addresses these shocks but also takes on "chronic stresses" that hamper recovery from these shocks. Those stresses include poor air quality, health disparities, crime, economic inequality, urban sprawl, and limited access to education.

"Stresses do not impact every Houstonian the same way," says the institute, which helped develop the Resilient Houston project.

Startups participating in Houston's Ion Smart and Resilient Cities Accelerator are tackling many of the same challenges that Resilient Houston is. The accelerator's second cohort launched in April with six startups.

Funded by Microsoft Corp. and Intel Corp., the accelerator "is committed to solving challenges Houstonians face every day," Christine Galib, director of the accelerator, said in an April release. "We connect participating startups with mentors, partners, and stakeholders so they gain access to the resources they need to build, validate, and scale their technologies. Together, we are building a safer, smarter, and more accessible city for all Houstonians."

Houston's push for resilience meshes with Turner's new role as chairman of the Resilient Cities Network. The network is a global city-led nonprofit that aims to "empower cities to help them build a safe, equitable, and sustainable future for all."

"The reach, achievements, and vision of the Resilient Cities Network are impressive. I'm honored to be part of an organization that supports the critical needs of vulnerable communities by implementing projects that address multiple shocks and stresses and are improving the lives of people," Turner says in a release.

Among other goals, the network strives to strengthen local economies and bolster local campaigns to combat climate change.

Supported by $1.8 million from Shell, the City of Houston joined the Resilient Cities Network in August 2018. Houston is the U.S. headquarters for Shell.

"A year after Hurricane Harvey, Houstonians can clearly say we didn't let the storm get the best of us. Nevertheless, there's still work to be done across a wide range of challenges that we share as a community," Bruce Culpepper, who then was president and U.S. chairman of Shell, said in a 2018 release about his company's backing of Resilient Houston.

"Building long-term resiliency is much more than disaster response," Culpepper added. "It's about enabling the people of our city to thrive."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings